Table 1.
Frequency of MBL2 (a) and MASP2 (b) genotypes in ovarian cancer patients and controls
| MBL2 gene | Group (n) | |||
|---|---|---|---|---|
| C (172) | NO (65) | BT (107) | OC (117) | |
| (a) | ||||
| A/A | 65.1 | 69.2 | 62.6 | 60.7 |
| YA/O | 23.3 | 24.6 | 22.4 | 20.5 |
| XA/O | 8.7 | 4.6 | 11.2 | 9.4 |
| O/O | 2.9 | 1.5 | 3.7 | 9.4a |
| XA/O + O/O | 11.6 | 6.2 | 15 | 18.8b |
| MASP2 gene | Group (n) | |||
|---|---|---|---|---|
| C (174) | NO (67) | BT (107) | OC (117) | |
| (b) | ||||
| A/A | 91.4 | 92.5 | 90.7 | 87.2 |
| A/G | 8.6 | 7.5 | 9.3 | 12.8 |
C, control group, including NO, patients with no ovarian pathology and BT, patients with benign ovarian tumours; OC, patients with primary ovarian cancer
a p = 0.03; OR 3.5 (vs C)
b p = 0.03; OR 3.5 (vs NO)